New clinical trial studies two-part treatment for patients with gastric cancer

Social worker holding patient's hand

Gastric cancer is a disease in which cancer cells form in the lining of the stomach. In about 40 percent of cases, stomach cancer spreads to the peritoneum, a thin layer of tissue that lines the abdomen and covers all the organs within it. A healthy peritoneum protects the organs and provides a barrier to infection. Jeremy Davis, M.D., of the Thoracic and Gastrointestinal Oncology Branch, is leading a study to see if a two-part treatment can improve survival for patients with stomach cancer that has spread to the peritoneum. Patients in this study will receive a highly concentrated, heated chemotherapy drug (hyperthermic intraperitoneal chemotherapy, or HIPEC) delivered directly to the abdomen during surgery to remove all or part of the stomach. Unlike chemotherapy that circulates throughout the body, HIPEC delivers the drug directly to cancer cells in the abdomen. For more information on this trial, visit:

Summary Posted: Mon, 05/01/2017